Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects
NCT ID: NCT00544934
Last Updated: 2016-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
42 participants
INTERVENTIONAL
2007-02-28
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
NCT04880291
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment
NCT01555008
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers
NCT01733108
Study of LY3016859 in Participants With Diabetic Nephropathy
NCT01774981
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
NCT01464320
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
250 mg
GLY-230
125, 250 0r 375 mg bid for 14 days
500 mg
GLY-230
125, 250 0r 375 mg bid for 14 days
750 mg
GLY-230
125, 250 0r 375 mg bid for 14 days
Placebo
Placebo
No drug administered
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GLY-230
125, 250 0r 375 mg bid for 14 days
Placebo
No drug administered
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glycadia
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurence Kennedy, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Maria del Pilar Solano, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Miami, Miami, Florida
Lis Cohen, D.O.
Role: PRINCIPAL_INVESTIGATOR
Suncoast Clinical Research, New Port Richey, Florida
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GLY-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.